早期与晚期放置胰管支架预防ERCP后胰腺炎:多中心随机临床试验方案
EVL试验为多中心、单盲、随机对照试验,拟纳入768例胆管插管困难并采用胰管导丝辅助胆管进入的ERCP患者,按1:1随机分入早期胰管支架置入组(ERC或EST后立即置入)与晚期胰管支架置入组(治疗性胆道操作全部完成后置入),主要结局为PEP发生率和严重程度,次要结局包括高淀粉酶血症、支架置入成功率及其他ERCP相关不良事件。
要点
- EVL试验比较早期与晚期胰管支架置入预防PEP,计划纳入768例胆管插管困难患者。
- 早期组在ERC或EST后立即置入支架,晚期组在治疗性胆道操作全部完成后置入。
- 主要结局为PEP发生率和严重程度,次要结局含高淀粉酶血症、支架置入成功率及其他ERCP相关不良事件。
核心结论
- EVL试验将为预防PEP时预防性胰管支架置入的最佳时机提供关键答案,研究结果可能改变ERCP的结局和实践。
研究设计与样本
- EVL试验为多中心、单盲、随机对照试验,计划纳入768例因胆管插管困难而在ERCP中采用胰管导丝辅助技术进入胆管的患者。
- 患者按1:1随机分入早期胰管支架置入组与晚期胰管支架置入组。
- 早期组在ERC或EST后立即置入胰管支架,晚期组在胆道取石或引流等治疗性胆道操作全部完成后置入胰管支架。
- 主要结局为PEP发生率和严重程度,次要结局为高淀粉酶血症、支架置入成功率及其他ERCP相关不良事件。
- 试验已在ClinicalTrials.gov注册(NCT06250803),注册日期为2024年2月9日。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreatic stenting has been shown to effectively lower the occurrence of post-ERCP pancreatitis (PEP) and reduce its severity. To date, no evidence exists to determine the optimal timing for pancreatic stent placement in prospective trials. Our aim is to compare early versus late pancreatic stent placement in preventing PEP among patients with naive papilla. METHODS/DESIGN: The EVL (Early stenting vs. Late stenting) trial is a multicenter, single-blind, randomized, and controlled trial. All patients with difficult biliary cannulation undergoing endoscopic retrograde cholangiopancreatography (ERCP) with pancreatic guidewire-assisted technique for biliary access will be told about the opportunity to participate in EVL research. In total, 768 patients will be randomly assigned (1:1) to two arms: (1) early pancreatic stent placement (EPSP) (a pancreatic stent will be placed immediately after endoscopic retrograde cholangiography (ERC) or endoscopic sphincterotomy (EST)) and (2) late pancreatic stent placement (LPSP) (a pancreatic stent will be placed after all completion of therapeutic biliary procedures, e.g., biliary stone removal or drainage). The primary outcome is the rate and severity of PEP. The secondary outcomes are hyperamylasemia, the rate of stenting success, and other ERCP-related adverse events (AEs). DISCUSSION: The EVL trial will provide essential answers regarding the optimal timing of prophylactic pancreatic stent placement in PEP prevention. Our findings could change ERCP outcomes and practices. TRIAL REGISTRATION: ClinicalTrials.gov NCT06250803. Registered on February 9, 2024. https://clinicaltrials.gov/study/NCT06250803?term=NCT06250803&rank=1 .
引用
- Wang S, Bai B, Hong J, et al. Early versus late pancreatic stent placement for preventing post-ERCP pancreatitis: protocol of a multicenter randomized clinical trial. Trials. 2025. PMID: 40462140. doi:10.1186/s13063-025-08878-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。